Uncertain Benefits: The specific advantages of GLP-3 supplementation or agonism remain unclear
Patients already taking statins see additional lipid improvements with GLP-1 medications 12
According to the FDAs draft guidance, PDURS provides a practical pathway to add companion software to the label to promote patient outcomes and safety
However, patients should consult their healthcare provider before adding any medications or supplements, especially those that might further slow gastrointestinal motility
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA in the UK
Healthcare providers typically review participant progress, body weight trends, and any side effects before making dose increases